Wells Fargo Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $31
ITeos Therapeutics Price Target Maintained With a $46.00/Share by HC Wainwright & Co.
ITeos Therapeutics Analyst Ratings
Piper Sandler Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $36
ITeos Therapeutics (ITOS) Receives a Buy From Piper Sandler
H.C. Wainwright Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $46
Wedbush Raises Price Target on ITeos Therapeutics to $25 From $21, Keeps Outperform Rating
Wells Fargo Maintains ITeos Therapeutics(ITOS.US) With Buy Rating, Maintains Target Price $31
Buy Rating Affirmed for ITeos Therapeutics Amid Promising Lung-201 Study Outcomes
J.P. Morgan Sticks to Its Buy Rating for ITeos Therapeutics (ITOS)
Wells Fargo Initiates Coverage On ITeos Therapeutics With Overweight Rating, Announces Price Target of $31
Wells Fargo Initiates ITeos Therapeutics(ITOS.US) With Buy Rating, Announces Target Price $31
ITeos Therapeutics Analyst Ratings
JP Morgan Maintains Overweight on ITeos Therapeutics, Lowers Price Target to $24
Buy Rating Affirmed for ITeos Therapeutics on Strong Financials and Promising Pipeline Updates
HC Wainwright & Co. : The iTeos Therapeutics (ITOS.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $44.00 to $46.00.
ITeos Therapeutics Analyst Ratings
Wedbush Adjusts ITeos Therapeutics' Price Target to $21 From $18, Maintains Outperform Rating
Analysts Offer Insights on Healthcare Companies: ITeos Therapeutics (ITOS), Rani Therapeutics Holdings (RANI) and Vor Biopharma (VOR)
ITeos Therapeutics Analyst Ratings